Personalized radioligand activity — using a diagnostic tracer dose to predict individual biodistribution before Lu-177-PSMA therapy, replacing one-size-fits-all activity
Fixed-activity radioligand therapy treats every patient the same way: a standard 7.4 GBq (200 mCi) infusion of Lu-177-PSMA-617, regardless of kidney function, tumor burden, or individual clearance kinetics. Pretherapy dosimetry inverts this logic — a small, sub-therapeutic "scout" activity of the same (or a matched) radiopharmaceutical is given first, purely to observe how this specific patient's body handles the drug, before any therapeutic decision is finalized.
The theranostic principle behind Lu-177-PSMA-617 and similar radioligand therapies is elegant: a small molecule or peptide is labeled with a beta-emitting radionuclide and binds a tumor-overexpressed target (prostate-specific membrane antigen, somatostatin receptor, etc.), delivering ionizing radiation directly to malignant cells while sparing most healthy tissue. But "most" is not "all" — the kidneys, salivary glands, and bone marrow all accumulate measurable activity, and how much varies dramatically between patients.
Glomerular filtration rate, tubular reabsorption efficiency, tumor burden (which acts as a competing "sink" for the radioligand), and prior nephrotoxic chemotherapy exposure can shift an individual patient's renal clearance by a factor of two or more relative to the population average used to justify a fixed 7.4 GBq activity. A patient with reduced renal function receiving the standard dose may accumulate a kidney dose well above safe limits; a patient with fast clearance and high tumor burden may be systematically under-dosed relative to what their kidneys could safely tolerate — leaving therapeutic benefit on the table.
The tracer (or "scout") activity is typically 10–20× lower than the therapeutic activity — commonly in the 1–2 GBq range for Lu-177-based agents, or a diagnostic Ga-68/Cu-64-PSMA PET acquisition used as a biodistribution surrogate in some protocols. Because absorbed dose to any organ scales approximately linearly with injected activity for a fixed pharmacokinetic profile, this low activity is high enough to be reliably quantified on SPECT/CT or blood sampling, yet low enough to deliver only a few percent of the radiation burden of a full treatment cycle.
Two pretherapeutic strategies dominate clinical practice:
• Same-radionuclide low-activity administration: a small dose of the exact therapeutic agent (e.g. 1–2 GBq Lu-177-PSMA) is given first, imaged over several days, and its kinetics extrapolated to the intended therapeutic activity. This avoids any cross-radionuclide biodistribution assumption.
• First-cycle dosimetry: rather than a separate pretherapy visit, some centers perform full dosimetric sampling around the first therapeutic cycle itself (still administered near a conservative activity), then use the resulting patient-specific kinetics to individualize activity for cycles 2 onward.
The tracer dose exploits the theranostic pairing directly — because Lu-177 emits both therapeutic beta particles and low-abundance gamma photons (208 keV, 113 keV) suitable for SPECT imaging, the same molecule that treats the tumor can also be imaged at low activity to predict its own future behavior at high activity. No separate diagnostic isotope is strictly required.
A single blood draw or scan tells you the activity present at one instant. To characterize how quickly a radioligand clears from blood and accumulates or washes out of the kidneys and tumor, multiple measurements spread across hours to days are required — enough to capture both the fast initial distribution phase and the slower terminal elimination phase that dominates cumulative radiation dose.
At each scheduled timepoint, two complementary measurements are typically collected:
• Venous blood samples: a small aliquot is drawn and its radioactivity concentration measured in a well counter. Blood clearance approximates whole-body clearance early on and is essential for bone-marrow dose estimation (the "blood-based" surrogate model), since marrow itself cannot be imaged with useful contrast.
• Quantitative SPECT/CT (or planar whole-body scintigraphy in resource-limited settings): reconstructs the 3D distribution of activity in the body, allowing organ-specific volumes of interest — both kidneys individually, salivary glands, spleen, liver, and each visible tumor lesion — to be segmented and their activity quantified in becquerels or megabecquerels.
A typical schedule for Lu-177-PSMA pretherapy dosimetry samples at approximately 1 hour, 4 hours, 24 hours, 48 hours, and sometimes 96–168 hours after injection, though abbreviated 2–3 point protocols exist that trade some accuracy for patient convenience and lower staff/scanner burden.
Every additional timepoint better constrains the shape of the underlying clearance curve, particularly the terminal elimination half-life, which dominates the time-integrated activity (the area under the time-activity curve) because it is multiplied by the longest time interval.
With only 2 timepoints, a mono-exponential clearance must be assumed, and any true bi-exponential (fast distribution + slow elimination) behavior gets averaged into a single effective half-life — introducing a systematic bias that can shift the derived organ dose by 10–25% in either direction depending on where the two samples happen to fall on the curve.
With 5–6 well-spaced timepoints spanning the full elimination phase, both the fast and slow clearance components can be resolved independently, and the fit's statistical uncertainty on the extrapolated TIAC shrinks substantially. The practical cost is patient burden: more clinic visits, more blood draws, more scanner time — which is precisely why abbreviated single- or few-timepoint methods (e.g., Hänscheid et al.'s effective half-life shortcut, Madsen et al.'s population-constrained fitting) remain an active area of methodological research.
Increasing the sampling schedule from 2 to 6 timepoints in this simulation visibly tightens the exponential fit around the scatter of measured points — reflecting the real trade-off nuclear medicine physicists navigate between dosimetric precision and clinical practicality.
Once the serial activity measurements are in hand, a pharmacokinetic model is fit to the data — almost always a sum of exponential terms describing uptake and clearance. Integrating this fitted curve over all time yields the Time-Integrated Activity Coefficient (TIAC, historically the "residence time"), the single number the MIRD dosimetry formalism needs to convert an organ's biodistribution into an absorbed radiation dose.
The Medical Internal Radiation Dose (MIRD) formalism decomposes absorbed dose calculation into two independent pieces: a purely biological/kinetic term (how much activity resided in the source organ, integrated over all time — the TIAC, units of MBq·h or equivalently hours) and a purely physical term (the "S-value," how much energy per unit activity reaches the target organ, derived from radionuclide physics and reference anatomical phantoms).
Absorbed Dose = TIAC × S-value
The tracer-derived TIAC is what makes dosimetry patient-specific: two patients receiving an identical injected activity can have TIACs that differ by a factor of two or three depending on renal function and tumor sink effect, translating directly into proportionally different absorbed doses for the same administered activity.
Before individualized dosimetry became practical, radiopharmaceutical dosing relied on population-average kinetic parameters derived from small validation cohorts — essentially assuming every patient clears the tracer the way an "average" patient in the original trial did. This is the assumption baked into any fixed-activity regimen.
When a patient's own tracer data is fit, the resulting individual curve frequently diverges from that population average — sometimes clearing faster (lower cumulative kidney exposure per GBq, room for a higher therapeutic activity), sometimes clearing markedly slower (higher risk per GBq, argument for a reduced activity or extended interval between cycles). Plotting the patient-specific fit against the faint population-average reference curve makes this divergence visually obvious and is precisely the comparison pretherapy dosimetry exists to enable.
Studies of pretherapeutic Lu-177-PSMA dosimetry (e.g. Sandström et al., Delker et al.) report kidney absorbed-dose-per-activity values across patient cohorts spanning roughly 0.3 to 0.9 Gy/GBq — nearly a three-fold range that a single fixed activity cannot safely and effectively serve for every patient simultaneously.
Absorbed dose is, to first approximation, linear in administered activity when the underlying biodistribution and clearance kinetics are held constant — a reasonable assumption when scaling from a low tracer activity to a therapeutic activity of the same radioligand within a several-fold range. This linearity is what allows a single low-activity tracer study to predict organ doses across an entire menu of candidate therapeutic activities without ever administering them.
Once the patient-specific TIAC is known from the tracer study, projecting an organ dose at any candidate therapeutic activity A (in GBq) is arithmetically simple:
Projected Dose(A) = (Dose observed at tracer activity / Tracer activity) × A
Equivalently, the tracer study yields a personal "dose-per-GBq" ratio for each organ of interest — kidneys, tumor lesions, salivary glands, marrow surrogate — and this ratio is simply multiplied across whatever candidate activities are clinically relevant, typically spanning the approved dose range for the agent (for Lu-177-PSMA-617, roughly 3.7 GBq at the low end up to 11.1 GBq for dose-escalated protocols, centered on the 7.4 GBq standard).
This extrapolation is what converts a single low-risk diagnostic measurement into a full projected dose-response table before any therapeutic decision commits the patient to a specific activity.
Linearity assumes the underlying biology does not change between tracer and therapeutic administration. In practice a few effects can introduce nonlinearity:
• Receptor saturation: at sufficiently high administered mass (not usually activity, but the carrier peptide mass co-injected with the radiolabel), target receptors can begin to saturate, altering uptake kinetics relative to the tracer study. PSMA-617 is typically given at sub-saturating peptide mass specifically to preserve this linearity.
• Tumor sink effect changes between cycles: as therapy proceeds and tumor burden shrinks, the "sink" competing with kidneys for radioligand uptake shrinks too, which is why dosimetry is often repeated before later cycles rather than assumed constant across an entire treatment course.
• Physiological changes over the treatment interval: renal function can decline (or occasionally improve) between the tracer study and the therapeutic administration, particularly in patients receiving concurrent nephrotoxic agents.
Despite these caveats, the linear extrapolation from a single low-activity tracer study remains the clinically dominant and best-validated approach to individualized activity planning in radioligand therapy.
Because the extrapolation is linear, the entire candidate-activity sweep from 3.7 to 11.1 GBq can be computed instantly from one tracer measurement — no additional scanning is required to evaluate every point along that range before choosing the final therapeutic activity.
The final step converts the extrapolated dose-versus-activity relationship into an actual clinical decision: the recommended therapeutic activity is the highest value that keeps the projected kidney absorbed dose (or its biologically effective dose, BED) under a pre-specified safety limit — not simply the highest allowed activity, and not the population-standard 7.4 GBq by default.
Some nuclear medicine centers have moved away from prescribing a fixed activity in gigabecquerels entirely, instead prescribing to a fixed kidney biologically effective dose (BED) limit — commonly drawn from decades of external-beam radiotherapy renal tolerance data (historically around 23–28 Gy in 2 Gy-equivalent fractions for a <5% risk of clinical nephropathy at 5 years, with radioligand-therapy-specific literature suggesting cumulative BED limits in the range of roughly 40 Gy(BED) across all treatment cycles).
Under this "dose-to-constraint" philosophy, the administered activity for each individual cycle — and indeed for each individual patient — is back-calculated from the patient's own tracer-derived kidney dose-per-GBq ratio, so that the kidney constraint is respected by construction rather than checked after the fact.
Plotted against candidate activity, tumor absorbed dose and kidney absorbed dose both rise linearly (per the extrapolation from Stage 4), but typically with different slopes reflecting the patient's individual tumor-to-kidney dose ratio. The kidney curve is compared against the fixed safety threshold; the activity at which the kidney curve crosses that threshold defines the maximum permissible activity for this patient.
Because tumor dose is monotonically increasing with activity (there is no equivalent "ceiling" imposed by tumor biology within the clinically relevant range), the optimal choice is simply the highest activity that does not cross the kidney constraint — maximizing anti-tumor effect subject to a hard safety boundary, rather than defaulting to whatever activity was standard for the population.
Multiple prospective and retrospective series in Lu-177-PSMA and Lu-177-DOTATATE therapy have shown that personalized dosimetry-guided activity selection can, in favorable-kinetics patients, permit escalation above the standard fixed activity while remaining within the same kidney safety margin — and conversely can flag patients who should receive a reduced activity or an extended inter-cycle interval to avoid exceeding it. The VIOLET dosimetry sub-study and multiple European academic centers (e.g. institutions following EANM dosimetry guidance) have published growing experience with this approach.
Adoption remains uneven: dosimetry-guided personalization requires SPECT/CT quantification infrastructure, dosimetry physicist time, and multi-visit scheduling that many community nuclear medicine practices do not yet have, so the field-wide standard is still largely a fixed 7.4 GBq per cycle. Randomized trials directly comparing fixed-activity versus dosimetry-personalized-activity regimens for overall survival and toxicity outcomes remain an active area of ongoing research as of the mid-2020s.
The core clinical promise of pretherapy dosimetry is not a single dramatic dose increase — it is precision: some patients safely receive more, some receive less, and every patient's activity is set by a number measured from their own body rather than assumed from the population they happen to statistically resemble.